.webp)
Pioneering Target Degrading Antibodies for Safer Cancer Therapies
At BioLoomics, we harness the vastness of protein design space using directed evolution in human cells.
Our Science
We Have a Unique Process To Discover Antibody Therapeutics That Traffic to Specific Subcellular Organelles
Learn More
Our Technology
We leverage activity-guided antibody library screening through Synthetic Biology, AI, Imaging, and Robotics to exponentially increase the rate of discovery of promising drug activity.
Learn More.webp)
About Us
Interdisciplinary pioneers driven by a common mission to create the next generation of antibody scaffolds.
We combine deep experience in synthetic biology, machine learning, and protein design to bring robust therapeutic solutions to patients with unmet needs.
Meet Our TeamLatest News
Pre-Seed Extension
BioLoomics closed a $575,000 round of pre seed extension funding on May 11, 2021..
September 18, 2023
OEDIT Grant Award
The Colorado OEDIT provides funding opportunities to small businesses in fourteen industries...
September 18, 2023
BioLoomics Closes $600k Pre-Seed Round to Launch Biosensing Drug Discovery Platform
We are excited to announce that on May 30, 2019, BioLoomics closed a $600,000 pre-seed round...
September 18, 2023
